![]() |
|
|
Vol. 288, Issue 3, 1167-1173, March 1999
Discovery Research Laboratory, Tanabe Seiyaku Co., Ltd., Saitama,
Japan
TA-993,
(
)-cis-3-acetoxy-5-(2-(dimethylamino)ethyl)-2,3-di-hydro-8-methyl-2-(4-methylphenyl)-1,5-benzothiazepin-4(5H)one maleate, a new 1,5-benzothiazepine derivative with l-cis
configuration, has a unique and selective increasing action on limb
blood flow with little influence on arterial pressure besides an
antiplatelet action. We studied the mechanism of increasing action of
TA-993 on limb blood flow in anesthetized dogs. In a canine
blood-perfused hindlimb preparation with a donor dog, TA-993
(100 µg/kg i.v.) did not increase femoral blood flow when
administered to the donor dog, but did when administered to a recipient
dog. TA-993 did not show the increasing action on femoral blood flow in
the presence of hexamethonium or phentolamine, whereas it did in the
presence of propranolol or atropine. TA-993 also showed a weak
increasing effect on heart rate, which was inhibited by any one of
these blockers. TA-993 (300 µg/kg i.v.) did not alter the
phenylephrine (1-100 ng/kg i.a.)- or the talipexole (3-100 ng/kg
i.a.)-induced increase in perfusion pressure in an autoperfused
hindlimb. These results suggest that the increasing action of TA-993 on
limb blood flow is mediated by the sympathetic nervous system but that
the adrenergic receptors are not likely to be the central point of action of this new agent. There is a possibility that the mechanism of
the increasing action on heart rate is different from that of its
increasing action on limb blood flow.